Inflammatory Indexes as Prognostic and Predictive Factors in Ovarian Cancer Treated with Chemotherapy Alone or Together with Bevacizumab. A Multicenter, Retrospective Analysis by the MITO Group (MITO 24)

A Farolfi, M Petrone, E Scarpi, V Gallà, F Greco, C Casanova, L Longo, G Cormio, M Orditura, A Bologna, L Zavallone, J Ventriglia, E Franzese, V Loizzi, D Giardina, E Pigozzi, Raffaela Cioffi, S Pignata, G Giorda, U de Giorgi

Research output: Contribution to journalArticle

Abstract

Background: The variability in progression-free survival (PFS) and overall survival (OS) among patients with epithelial ovarian cancer (EOC) makes it difficult to reliably predict outcomes. A predictive biomarker of bevacizumab efficacy as first-line therapy in EOC is still lacking. Objective: The MITO group conducted a multicenter, retrospective study (MITO 24) to investigate the role of inflammatory indexes as prognostic factors and predictors of treatment efficacy in FIGO stage III–IV EOC patients treated with first-line chemotherapy alone or in combination with bevacizumab. Patients and Methods: Of the 375 patients recruited, 301 received chemotherapy alone and 74 received chemotherapy with bevacizumab. The pre-treatment neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and systemic immune inflammation index (SII) were evaluated to identify a potential correlation with PFS and OS in both the overall population and the two treatment arms. Results: In the overall population, the PFS and OS were significantly longer in patients with low inflammatory indexes (p <0.0001). In multivariate analyses, the NLR was significantly associated with OS (p = 0.016), and the PLR was significantly associated with PFS (p = 0.024). Inflammatory indexes were significantly correlated with patient prognosis in the chemotherapy-alone group (p <0.0001). Patients in the chemotherapy with bevacizumab group with a high NLR had a higher PFS and OS (p = 0.026 and p = 0.029, respectively) than those in the chemotherapy-alone group. Conversely, PFS and OS were significantly poorer in patients with a high SII (p = 0.024 and p = 0.017, respectively). Conclusion: Our results suggest that bevacizumab improves clinical outcome in patients with a high NLR but may be detrimental in those with a high SII. © 2018 Springer International Publishing AG, part of Springer Nature
Original languageEnglish
Pages (from-to)469-479
Number of pages11
JournalTargeted Oncology
Volume13
Issue number4
DOIs
Publication statusPublished - 2018

Fingerprint

Ovarian Neoplasms
Drug Therapy
Disease-Free Survival
Lymphocytes
Survival
Neutrophils
Inflammation
Blood Platelets
Bevacizumab
Population
Multicenter Studies
Therapeutics
Multivariate Analysis
Retrospective Studies
Biomarkers
Ovarian epithelial cancer

Cite this

Inflammatory Indexes as Prognostic and Predictive Factors in Ovarian Cancer Treated with Chemotherapy Alone or Together with Bevacizumab. A Multicenter, Retrospective Analysis by the MITO Group (MITO 24). / Farolfi, A; Petrone, M; Scarpi, E; Gallà, V; Greco, F; Casanova, C; Longo, L; Cormio, G; Orditura, M; Bologna, A; Zavallone, L; Ventriglia, J; Franzese, E; Loizzi, V; Giardina, D; Pigozzi, E; Cioffi, Raffaela; Pignata, S; Giorda, G; de Giorgi, U.

In: Targeted Oncology, Vol. 13, No. 4, 2018, p. 469-479.

Research output: Contribution to journalArticle

Farolfi, A, Petrone, M, Scarpi, E, Gallà, V, Greco, F, Casanova, C, Longo, L, Cormio, G, Orditura, M, Bologna, A, Zavallone, L, Ventriglia, J, Franzese, E, Loizzi, V, Giardina, D, Pigozzi, E, Cioffi, R, Pignata, S, Giorda, G & de Giorgi, U 2018, 'Inflammatory Indexes as Prognostic and Predictive Factors in Ovarian Cancer Treated with Chemotherapy Alone or Together with Bevacizumab. A Multicenter, Retrospective Analysis by the MITO Group (MITO 24)', Targeted Oncology, vol. 13, no. 4, pp. 469-479. https://doi.org/10.1007/s11523-018-0574-1
Farolfi, A ; Petrone, M ; Scarpi, E ; Gallà, V ; Greco, F ; Casanova, C ; Longo, L ; Cormio, G ; Orditura, M ; Bologna, A ; Zavallone, L ; Ventriglia, J ; Franzese, E ; Loizzi, V ; Giardina, D ; Pigozzi, E ; Cioffi, Raffaela ; Pignata, S ; Giorda, G ; de Giorgi, U. / Inflammatory Indexes as Prognostic and Predictive Factors in Ovarian Cancer Treated with Chemotherapy Alone or Together with Bevacizumab. A Multicenter, Retrospective Analysis by the MITO Group (MITO 24). In: Targeted Oncology. 2018 ; Vol. 13, No. 4. pp. 469-479.
@article{d3a9112ed8404b27ad2fa48ba23e85a5,
title = "Inflammatory Indexes as Prognostic and Predictive Factors in Ovarian Cancer Treated with Chemotherapy Alone or Together with Bevacizumab. A Multicenter, Retrospective Analysis by the MITO Group (MITO 24)",
abstract = "Background: The variability in progression-free survival (PFS) and overall survival (OS) among patients with epithelial ovarian cancer (EOC) makes it difficult to reliably predict outcomes. A predictive biomarker of bevacizumab efficacy as first-line therapy in EOC is still lacking. Objective: The MITO group conducted a multicenter, retrospective study (MITO 24) to investigate the role of inflammatory indexes as prognostic factors and predictors of treatment efficacy in FIGO stage III–IV EOC patients treated with first-line chemotherapy alone or in combination with bevacizumab. Patients and Methods: Of the 375 patients recruited, 301 received chemotherapy alone and 74 received chemotherapy with bevacizumab. The pre-treatment neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and systemic immune inflammation index (SII) were evaluated to identify a potential correlation with PFS and OS in both the overall population and the two treatment arms. Results: In the overall population, the PFS and OS were significantly longer in patients with low inflammatory indexes (p <0.0001). In multivariate analyses, the NLR was significantly associated with OS (p = 0.016), and the PLR was significantly associated with PFS (p = 0.024). Inflammatory indexes were significantly correlated with patient prognosis in the chemotherapy-alone group (p <0.0001). Patients in the chemotherapy with bevacizumab group with a high NLR had a higher PFS and OS (p = 0.026 and p = 0.029, respectively) than those in the chemotherapy-alone group. Conversely, PFS and OS were significantly poorer in patients with a high SII (p = 0.024 and p = 0.017, respectively). Conclusion: Our results suggest that bevacizumab improves clinical outcome in patients with a high NLR but may be detrimental in those with a high SII. {\circledC} 2018 Springer International Publishing AG, part of Springer Nature",
author = "A Farolfi and M Petrone and E Scarpi and V Gall{\`a} and F Greco and C Casanova and L Longo and G Cormio and M Orditura and A Bologna and L Zavallone and J Ventriglia and E Franzese and V Loizzi and D Giardina and E Pigozzi and Raffaela Cioffi and S Pignata and G Giorda and {de Giorgi}, U",
year = "2018",
doi = "10.1007/s11523-018-0574-1",
language = "English",
volume = "13",
pages = "469--479",
journal = "Targeted Oncology",
issn = "1776-2596",
publisher = "Springer Paris",
number = "4",

}

TY - JOUR

T1 - Inflammatory Indexes as Prognostic and Predictive Factors in Ovarian Cancer Treated with Chemotherapy Alone or Together with Bevacizumab. A Multicenter, Retrospective Analysis by the MITO Group (MITO 24)

AU - Farolfi, A

AU - Petrone, M

AU - Scarpi, E

AU - Gallà, V

AU - Greco, F

AU - Casanova, C

AU - Longo, L

AU - Cormio, G

AU - Orditura, M

AU - Bologna, A

AU - Zavallone, L

AU - Ventriglia, J

AU - Franzese, E

AU - Loizzi, V

AU - Giardina, D

AU - Pigozzi, E

AU - Cioffi, Raffaela

AU - Pignata, S

AU - Giorda, G

AU - de Giorgi, U

PY - 2018

Y1 - 2018

N2 - Background: The variability in progression-free survival (PFS) and overall survival (OS) among patients with epithelial ovarian cancer (EOC) makes it difficult to reliably predict outcomes. A predictive biomarker of bevacizumab efficacy as first-line therapy in EOC is still lacking. Objective: The MITO group conducted a multicenter, retrospective study (MITO 24) to investigate the role of inflammatory indexes as prognostic factors and predictors of treatment efficacy in FIGO stage III–IV EOC patients treated with first-line chemotherapy alone or in combination with bevacizumab. Patients and Methods: Of the 375 patients recruited, 301 received chemotherapy alone and 74 received chemotherapy with bevacizumab. The pre-treatment neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and systemic immune inflammation index (SII) were evaluated to identify a potential correlation with PFS and OS in both the overall population and the two treatment arms. Results: In the overall population, the PFS and OS were significantly longer in patients with low inflammatory indexes (p <0.0001). In multivariate analyses, the NLR was significantly associated with OS (p = 0.016), and the PLR was significantly associated with PFS (p = 0.024). Inflammatory indexes were significantly correlated with patient prognosis in the chemotherapy-alone group (p <0.0001). Patients in the chemotherapy with bevacizumab group with a high NLR had a higher PFS and OS (p = 0.026 and p = 0.029, respectively) than those in the chemotherapy-alone group. Conversely, PFS and OS were significantly poorer in patients with a high SII (p = 0.024 and p = 0.017, respectively). Conclusion: Our results suggest that bevacizumab improves clinical outcome in patients with a high NLR but may be detrimental in those with a high SII. © 2018 Springer International Publishing AG, part of Springer Nature

AB - Background: The variability in progression-free survival (PFS) and overall survival (OS) among patients with epithelial ovarian cancer (EOC) makes it difficult to reliably predict outcomes. A predictive biomarker of bevacizumab efficacy as first-line therapy in EOC is still lacking. Objective: The MITO group conducted a multicenter, retrospective study (MITO 24) to investigate the role of inflammatory indexes as prognostic factors and predictors of treatment efficacy in FIGO stage III–IV EOC patients treated with first-line chemotherapy alone or in combination with bevacizumab. Patients and Methods: Of the 375 patients recruited, 301 received chemotherapy alone and 74 received chemotherapy with bevacizumab. The pre-treatment neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and systemic immune inflammation index (SII) were evaluated to identify a potential correlation with PFS and OS in both the overall population and the two treatment arms. Results: In the overall population, the PFS and OS were significantly longer in patients with low inflammatory indexes (p <0.0001). In multivariate analyses, the NLR was significantly associated with OS (p = 0.016), and the PLR was significantly associated with PFS (p = 0.024). Inflammatory indexes were significantly correlated with patient prognosis in the chemotherapy-alone group (p <0.0001). Patients in the chemotherapy with bevacizumab group with a high NLR had a higher PFS and OS (p = 0.026 and p = 0.029, respectively) than those in the chemotherapy-alone group. Conversely, PFS and OS were significantly poorer in patients with a high SII (p = 0.024 and p = 0.017, respectively). Conclusion: Our results suggest that bevacizumab improves clinical outcome in patients with a high NLR but may be detrimental in those with a high SII. © 2018 Springer International Publishing AG, part of Springer Nature

U2 - 10.1007/s11523-018-0574-1

DO - 10.1007/s11523-018-0574-1

M3 - Article

VL - 13

SP - 469

EP - 479

JO - Targeted Oncology

JF - Targeted Oncology

SN - 1776-2596

IS - 4

ER -